




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/14, 9/16, 9/20, 9/48, 31/20, 9/107, 38/00		A1	(11) International Publication Number: WO 00/00179
			(43) International Publication Date: 6 January 2000 (06.01.00)
(21) International Application Number: PCT/KR99/00341		(81) Designated States: AU, CA, CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 28 June 1999 (28.06.99)			
(30) Priority Data: 1998/24563 27 June 1998 (27.06.98) KR 1999/24437 26 June 1999 (26.06.99) KR		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): WON JIN BIOPHARMA CO., LTD. [KR/KR]; 1626-2, Socho-dong, Socho-ku, Seoul 137-070 (KR).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): LEE, Beom, Jin [KR/KR]; #501-213 Hyundai 5th Apt., Hupyoung 2-dong, Chuncheon-si, Kangwon-do 200-162 (KR).			
(74) Agent: LEE, Won-Hee; Suite 805, Sung-ji Heights II, 642-16 Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).			

(54) Title: SOLID DISPERSED PREPARATION OF POORLY WATER-SOLUBLE DRUG CONTAINING OIL, FATTY ACID OR MIXTURES THEREOF



(57) Abstract

Disclosed is a solid dispersed preparation for poorly water-soluble drugs, which is prepared by dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture. The solid dispersed preparation can be formulated into a power formulation or a granule formulation. The solid dispersed preparation is improved in the solubility of poorly water-soluble drugs in the gastro-intestinal tract, resulting in a great increase in the bioavailability of the drugs. In addition, the solid dispersed preparation gives the pharmaceutical solutions to the problems that the conventional semi-solid or liquid preparations possess, enabling medicinally effective, poorly water-soluble compounds to be formulated, molded and processed, quickly and in an economically favorable manner without use of any organic solvent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

SOLID DISPERSED PREPARATION OF POORLY WATER-SOLUBLE DRUG
CONTAINING OIL, FATTY ACID OR MIXTURES THEREOF

BACKGROUND OF THE INVENTION

5

Field of the Invention

The present invention relates to a solid dispersed preparation for poorly water-soluble drugs or biologically active substances. More particularly, this invention
10 relates to a solid dispersed preparation which allows poorly water-soluble drugs to be increased in the uptake efficiency in the gastro-intestinal track and is convenient to make in a pharmaceutical formulation.

15 Description of the Prior Art

A good many drugs poorly dissolve in water. When being administered to a body, these poorly water-soluble drugs have so low solubility and releasing rate in digestive juices as to retard their absorption, resulting the
20 bioavailability decreased. In order to solve this problem, various preparation methods were developed with the aim of solubilizing these poorly water-soluble drugs and increasing their releasing rates. For instance, there have been reported many methods for improving the
25 bioavailability of drugs, including micronization, formation of micelles by use of surfactant, solvent deposition, utilization of dry elixirs, co-precipitation

by use of inert water-soluble carriers, solid-dispersion and formation of inclusion complexes using cyclodextrins.

In conducting these methods, however, the drugs to be administered do not show a constant increase in solubility.

5 Thus, they are problematic in terms of preparation, commercialization, and efficiency.

For the poorly water-soluble drugs, which are also poor in internal uptake, there have been made attempts to enhance their bioavailability upon administration.

10 However, the dosage forms developed thus far, are of semi-solid or liquid form, giving disadvantages in pharmaceuticals, especially in formulating, molding and processing.

15 SUMMARY OF THE INVENTION

We, the inventors made the intensive and thorough research on the formulation of poorly water-soluble drugs, to improve the bioavailability of the drugs upon
20 administration. As a result, we found that the dispersion or solution of the poorly water-soluble drugs in oils, fatty acids or mixtures thereof, followed by mixing with a water-soluble polymer matrix allowed the drugs to efficiently release in the gastro-intestinal tract and the
25 mixture can be formed into a solid form.

Therefore, it is an object of the present invention to provide a solid dispersed preparation which improves the

bioavailability of poorly water-soluble drugs by enhancing the release of the drugs in the gastro-intestinal tract.

It is another object of the present invention to provide a solid dispersed preparation which can be prepared
5 by simple and convenient process with an economical benefit.

According to the present invention, a solid dispersed preparation for poorly water-soluble drugs is prepared by dissolving or dispersing the drugs in an oil, a fatty acid
10 or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture.

BRIEF DESCRIPTION OF THE DRAWINGS

15 **Fig. 1** is a graph in which the plasma concentration of cyclosporine is plotted against the times after administrating the solid dispersed preparations of the present invention (closed rectangle and closed triangle) and a commercially available preparation (Neoral, closed
20 lozenge);

Fig. 2 is a graph in which the plasma concentration of aceclofenac is plotted against the times after orally administrating aceclofenac powder (closed circle) and the solid dispersed preparation of the present invention (open
25 circle, oleic acid 5%) to rats;

Fig. 3 is a graph in which the plasma concentration of cyclosporine is plotted against the times after

administering the solid dispersed preparation of the present invention (closed circle, capsule containing 100 mg of the preparation) and a commercially available preparation (open circle, Airtal capsule 100 mg) to beagle dogs;

Fig. 4 is a graph in which the plasma concentration of aceclofenac is plotted against the times after orally administering the solid dispersed preparation of the present invention (closed circle, capsule containing 100 mg of the preparation) and a commercially available preparation (open circle, Airtal capsule 100 mg) to humans; and

Fig. 5 is a graph in which the plasma concentration of cisapride is plotted against the times after orally administering the solid granular preparations of the present invention (open circle, bead 10 mg) and a commercially available preparation (closed circle, prepulsid 10 mg) to humans.

DETAILED DESCRIPTION OF THE INVENTION

Hereinafter, the present invention will be described in detail.

In accordance with the present invention, there is provided a solid dispersed preparation for poorly water-soluble drugs, which is prepared by dispersing or dissolving the drugs in an oil, a fatty acid or a mixture

thereof, incorporating the dispersion or solution into a water-soluble polymer matrix and drying this mixture.

In particular, this invention provides two types of fomulation, i.e., the solid powdery preparation and the
5 solid granular preparation.

The preparation method of the solid dispersed powders comprises the following steps; Dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or the mixture thereof; mixing with the water-soluble polymer
10 matrix; drying the mixture; and grinding the pellet into powders.

In addition, the preparation method of the solid dispersed granules comprises the following steps;
Dissolving or dispersing the poorly water-soluble drugs in
15 an oil, a fatty acid or the mixture thereof; mixing with the water-soluble polymer matrix; spraying onto a pharmaceutically acceptable nucleus, resulting the granules. In a preferred embodiment, the pharmaceutically acceptable nucleus may be a sugar sphere.

20 The solid dispersed powdery preparation or the solid dispersed granular preparation of this invention can be formulated into the pharmaceutically acceptable medicines for internal use such as powders, granules, tablets and capsules.

25 Hereinafter, the word "solid dispersed preparation" means "solid dispersed powdery preparation", "solid dispersed granular preparation" or the both.

In this regard, the oil, the fatty acid or the mixture thereof may be used alone or in a form of an emulsion or microemulsion inclusive of itself. When dispersing or dissolving poorly water-soluble drugs in the oil, fatty acid or mixture thereof, a surfactant may be added together.

Further, the water-soluble polymer matrix may be used alone or in combination with another water-soluble matrix.

Illustrative examples of the oil that can be used in the preparation of the present invention include lipid additives, such as α -bisabolol, stearyl glycerphosphate, salicylic acid, tocopheryl acetate, a mixture of water, alcohol and Perilla extract, sodium hyaluronate, panthenol, propylene glycol and apple (*Pirus Malus*), propylene glycol and pineapple, ivy (*Hedera halix*) extract and 1,3-B.G, peach (*Prums persica*) leaf extract, hydrolyzed soy flour, wheat (*Triticum Vulgare*) protein, birch (*Betula alba*) extract and 1,3-B.G, burdock (*Arctium majus*) extract and 1,3-B.G; liposomes; phosphatidylcholines; esters, such as glyceryl stearate, captylic/capric triglyceride, cetyl octanolate, isopropyl myristate, 2-ethylene isopelagonate, di-C12-13 alkyl malate, ceteatyl octanoate, butylene glycol dicaptylate/dicaprate, isononyl isostearate, isostearyl isostearate, coco-captylate/caprate, cetyl octanoate, octyldodecyl myristate, cetyl esters, C10-30 cholesterol/lanosterol ester, hydrogenated castor oil, monoglycerides, diglycerides, and triglycerides; hydrocarbons, such as beeswax, canauba wax, sucrose

distearate, PEG-8 beeswax and candelilla (*euphorbia cerifera*) wax; mineral oils such as ceresin and ozokerite; vegetable oils such as macadamia ternifolia nut oil, hydrogenated hi-erucic acid rape seed oil, olive oil, jojoba oil, hybridsunflower (*Helianthus annuus*) oil, neem (*melia azadirachta*) seed oil, dog rose (*rosa canina*) lips oil with preference to mineral oils, squalene, squalane, monoglycerides, diglycerides, triglycerides, medium-chain glyceride, myglyol, cremophor, hydrogenated castor oil, corn oil, Perilla oil, cotton seed oil and lipid-soluble vitamins.

As for the fatty acid, it is preferable to use oleic acid, cetyl alcohol, stearyl alcohol, stearic acid, myristic acid, linoleic acid or lauric acid. More preferable is to use oleic acid, linoleic acid, or isopropyl myristate.

As the water-soluble matrix, polyethylene glycol (PEG), carbowax or polyvinyl pyrrolidone (PVP) is available. Aforementioned water-soluble matrix may be used in combination with other matrixes, examples of which include water-soluble matrices such as gelatin, gum, carbohydrates, celluloses, polyvinyl alcohol, polyacrylic acid, inorganic compounds and mixtures thereof; and enteric matrices such as hydroxypropylmethylcellulose acetyl succinate (HPMCAS), cellulose acetate phthalate, shellac, zein, polyvinyl acetate phthalate, Eudragit L100, Eudragit S100, sodium arginate and poly-L-lysine.

In order to enhance the dispersion or dissolution of poorly water-soluble drugs in the oil, fatty acid or their mixture, a surfactant may be added, which is selected from the group comprising glyceryl stearate, polysorbate 60, polysorbate 80, sorbitan trioleate, sorbitan sesquioleate, sorbitan stearate, PEG-20 glyceryl isostearate, ceteth-25, PEG-60 hydrogenated castor oil, nonoxynol-15, PEG-6-decyltetradeceth-20, dimethicone copolyol, glyceryl diisostearate, ceteth-24, cetearyl alcohol, polyoxylethylene nonyphenyl ether, PEG-40 hydrogenated castor oil, cetyl dimethicone copolyol, polyglyceryl-3-methylglucose distearate, PEG-100 stearate, sorbitan isostearate, sodium lauryl glutamate, disodium cocoamphodiacetate, lauric acid diethanolamide, coconut fatty acid diethanolamide, N,N-bis-(2-hydroxy ethyl)-cocomide, and cocoamidopropyl betain.

The solid dispersed preparation of the present invention can be applied for all the poorly water-soluble drugs and preferably for ketoconazole; itraconazole and its derivatives; cyclosporine; cisapride; acetaminophen; aspirin; acetylsalicylic acid; indomethacin; naproxen; warfarin; papaverine; thiabendazole; miconazole; cinnarizine; doxorubicin; omeprazole; cholecalciferol; melphalan; nifedipine; digoxin; benzoic acid; tryptophan; tyrosine; phenylalanine; aztreonam; ibuprofen; phenoxymethylpenicillin; thalidomide; methyltestosterone; prochlorperazine; hydrocortisone; dideoxypurine

nucleoside; vitamin D₂; sulfonamide; sulfonylurea; p-aminobenzoic acid; melatonin; benzylpenicillin; chlorambucil; diazepam; digitoxin; hydrocortisone butyrate; metronidazole benzoate; tolbutamide; 5 prostaglandin E₁ (PGE₁); fludrocortisone; griseofulvin; miconazole nitrate; leukotriene B₄ antagonist; propranolol; theophylline; flubiprofen; sodium benzoate; benzoic acid; riboflavin; benzodiazepine; phenobarbital; glyburide; sulfadiazine; sulfaethylthiadiazole; sodium 10 diclofenac; aceclofenac; phenyroin; hioridazinehydrochloride; bropirimine; hydrochlorothiazide; fluconazole; acyclovir; bucillamine; ciproflouxacin; acetyl-L-carnitine; baclofen; sodium alendronate; lovocarnitine; nimodipine or nimodifine; 15 atenolol; provastatin sodium; lovastatin; isotretinoin; etidronate disodium; doxifluridine; fosfomycin calcium; sotepine; epinastine hydrochloride; carvedilol; epinastine hydrochloride; carvedilol; fosinopril;trandolapril; etretinate cap; metergoline; 20 mercaptopurine; vancomycin hydrochloride; cefixime; cefuroxim axetil; dirithramycin; and dadanosin and more preferably for ketoconazole, itraconazole and its derivatives, cisapride, cyclosporine and nifedipine.

Over conventional methods, the present invention has 25 an advantage, in that, the solid dispersed preparation can be prepared with ease and show high efficiency in absorption and release.

First, a poorly water-soluble medicine is homogeneously mixed and dispersed in an oil, fatty acid or their mixture and added in water-soluble polymer matrices molten at room temperature or about 60-80 °C, after which the
5 resulting mixture is cooled rapidly to room temperature and dried in an oven for 12 hours or more. The dried pellet is powdered in a mortar and passed through a sieve to give powder which is uniform in particle size. As aforementioned, when the drug is dispersed or dissolved in
10 the oil, fatty acid or their mixture, the oil, fatty acid or their mixture may be emulsified or micro-emulsified. In this case, a surfactant may be added to the solution.

Alternatively, after the homogeneous dispersion of the poorly water-soluble drug is added in the water-soluble
15 polymer matrix molten at about 60-80 °C, it may be sprayed to pharmaceutically acceptable nucleus to give a granule.

As a consequence of an examination which was made on the solubility of the solid dispersed preparation in distilled water, artificial intestinal juice and
20 artificial gastric juice, the solubility of the solid dispersed preparation is found to be better than those of poorly water-soluble drugs themselves. Particularly, a great advance can be brought into the solubility of poorly water-soluble drugs when they are incorporated into a solid
25 dispersed preparation containing oleic acid or micro-emulsified oleic acid.

The data obtained from the experiments in which the

solid dispersed preparations of the present invention are eluted in artificial gastric juice and artificial intestinal juice, show that the solid dispersed preparations of the present invention are superior to the
5 poorly water-soluble drugs themselves in releasing rate.

A significant improvement in releasing rate is observed when a solid dispersed preparation containing oleic acid or microemulsified oleic acid is used. In the artificial intestinal juice, a severer condition in which for drugs to
10 dissolve, rather than in the artificial gastric juice, the improvement in the releasing rate by virtue of the solid dispersed preparation is more apparent.

Through an experiment which is conducted for examining the uptake efficiency of poorly water-soluble drugs in the
15 gastro-intestinal tract, the superiority of the solid dispersed preparation according to the present invention is also demonstrated. Even when only a water-soluble matrix is used, the uptake efficiency of the drugs is minutely increased. In particular, the uptake efficiency of drugs
20 in the gastro-intestinal tract is remarkably improved when they are incorporated in a solid dispersed preparation using oleic acid-containing microemulsions.

In addition, comparison of the plasma concentration of target drug molecule after oral administration between the
25 solid dispersed preparation and conventional preparations, is helpful in understanding the present invention. As a result, similar levels are observed, suggesting that the

solid dispersed preparation of the present invention can substitute for conventional preparations when account is taken of pharmaceutical aspects.

A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.

Following are the compositions of emulsions and microemulsions used in Examples.

10

EMULSIONS**PREPARATION EXAMPLE I**

15	Waxes	Composition (%)
	KALCHOL 6870	1.800
	EMERSOL 132	1.000
	Multi-Wax W-445	1.700
20	Emulsifiers	
	ATLAS G-144	1.800
	ATLAS G-610	1.900
	ATMOS 370	0.800
	KM-105	2.000
25	Oils	
	CRODALAN SWL	1.500

	LEXOL GT 865	4.000
	NIKKOL CIO	4.000
	SEPERIOR JOJOBA OIL	1.000
	SF 1202	0.200
5	KF-96(100CS)	0.300
	DRAKEOL 7	5.000
	Squalane	2.000
	dl-a-Tocopheryl Acetate	0.100
	POLYOLPERPOLYMER-2	0.200
10		
	Aqueous Phase	
	DI-WATER	60.852
	glycerin	2.000
	P.G	7.000
15	NATURAL EXT.AP	0.500
	LUBRAGEL CG	0.200
	Carbopo 1940	0.100
	KELTROL F	0.020
	NaOH	0.028

20

PREPARATION EXAMPLE II

	Waxes	
	KALCHOL 6870	1.800
25	EMERSOL 132	1.000
	Multi-wax W-445	1.700

Emulsifiers

	RHEODOL AO-15	0.800
	RHEODOL MS-162	2.000
	RHEODOL TW-S120	1.900
5	KM-105	2.000

Oils

	CRODALAN SWL	1.500
	LEXOL GT 865	5.000
10	NIKKOL CIO	2.500
	Macadamia ternifolia nut oil	1.000
	SF 1202	0.300
	KF-96(100CS)	0.300
	DRAKEOL 7	7.000
15	Squalane	0.500
	dl-a-Tocopheryl Acetate	0.100
	POLYOLPERPOLYMER-2	0.100

Aqueous phase

20	DI-WATER	61.780
	glycerin	2.000
	1.3-B.G	6.000
	NATURAL EXT.AP	0.300
	LUBRAGEL CG	0.200
25	Carbopol 940	0.100
	KELTROL F	0.020
	TEA	0.100

PREPARATION EXAMPLE III

Waxes

	KALCHOL 6870	0.500
5	EMERSOL 132	0.500
	Beeswax	0.400

Emulsifiers

	ATLAS G-114	2.200
10	ATLAS G-610	0.800
	ATMOS 370	0.800
	KM-105	0.700

Oils

15	CRODALAN SWL	0.500
	LEXOL GT 865	3.000
	NIKKOL CIO	3.000
	SUPERIOR JOJOGA OIL	0.500
	SR 1202	0.200
20	KF-96(100CS)	0.100
	DRAKEOL 7	3.000
	Squalane	0.500
	dl-a-Tocopheryl Acetate	0.100
	POLYOLPERPOLYMER-2	0.200

25

Aqueous phase

	DI-WATER	74.146
--	----------	--------

	Glycerin	2.000
	P.G	6.000
	NATURAL EXT.AP	0.500
	LUBRAGEL CG	0.200
5	Carbopol 940	0.100
	KELTROL F	0.020
	NaOH	0.0336

PREPARATION EXAMPLE IV

10

Waxes

	KALCHOL 6870	0.400
	EMERSOL 132	0.500
	Multi-Wax W-445	0.400

15

Emulsifiers

	RHEODOL AO-15	0.800
	RHEODOL MS-165	2.200
	RHEODOL TW-S120	0.800

20

	KM-105	0.600
--	--------	-------

Oils

	CRODALAN SWL	0.500
	LEXOL GT 865	3.000

25

	NIKKOL CIO	2.000
	Macadamia ternifolia nut oil	1.000
	SF 1202	0.400

	DRAKEOL 7	4.500
	Squalane	0.500
	dl-a-tocopheryl acetate	0.100
	POLYOLPERPOLYMER-2	0.100
5	Aqueous phase	
	DI-WATER	73.480
	glycerin	2.000
	1,3-B.G	6.000
10	NATURAL EXT.AP	0.300
	LUBRAGEL CG	0.200
	Cabopol	0.100
	KELTROL F	0.020
	TEA	0.100

15

MICROEMULSIONS**PREPARATION EXAMPLE V**

20 Waxes

Cetyl Alcohol	3.000
---------------	-------

Emulsifiers

	NIKKOL HCO-60	5.000
25	RHEODOL TW-0120	5.000
	Cremophor EL	20.000

Oils

I.P.M	5.000
CAPTEX	5.000

5 Aqueous phase

DI-WATER	52.000
Ethanol	5.000

PREPARATION EXAMPLE VI

10

Emulsifiers

NIKKOL HCO-60	5.000
RHEODOL TW-0120	5.000
Cremophor EL	5.000

15

Oils

I.P.M	5.000
Lanolin oil	5.000
CAPTEX	5.000

20

Aqueous phase

DI-WATER	50.000
----------	--------

PREPARATION EXAMPLE VII

25

Surfactant

LABRASOL	15.000
----------	--------

	Surfactant Aid	
	Polyglyceryl oleate	5.000
	PLURL OLEIQUE	5.000
5	Oil phase	
	LABRAFIL M1994CS	4.500
	Sub-Solvent	
10	Transcutol	5.000
	Aqueous phase	
	Phosphate buffer(pH 6)	64.500

15 PREPARATION EXAMPLE VIII

	Oil phase	
	GELUCIRE 44/14	11.429
	GELUCIRE 48/09	11.429
20	Surfactant	
	LABRAFAC CM 10	10.714
	Surfactant Aid	
	LAUROGLYCOL	7.143
25	Transcutol	59.285

PREPARATION EXAMPLE IX

Aqueous Phase

	Water (Buffer)	57,050
	Physiological Saline Solution	4,000
5	Glucose	1,000
	Propylene Glycol PEG 300,400	5,000
	Glycerol	5,000

Oil Phase

10	Fatty Acid Esters	5,000
	Modified Vegetable Oil	0.500
	Silicon Oil	0.500

Surfactant Aid

15	Long Chain Alcohol	3,750
	Glycol Derivative	2,500
	Propylene Glycol Derivative	1,200
	Polyglycerol Derivative	4,500

20 Surfactant

	Non-ionic Surfactant	10,000
--	----------------------	--------

PREPARATION EXAMPLE X

25 Oil Phase

	Oleic Acid	6,250
--	------------	-------

	Surfactant	
	Tween 80	12,500
	Surfactant Aid	
5	Transcutol	8,750
	Aqueous Phase	
	Water	72,500

10

PREPARATION EXAMPLE XI

	Oil Phase	
	Captex	5,000
15	Surfactant	
	Cremophor	12,500
	Surfactant Aid	
	Transcutol	6,250
20	Aqueous Phase	
	Water	76,250

COMPARATIVE EXAMPLE I

25

After being melted at about 70 °C, 90 g of PEG 6000 was added with 10 g of ketoconazole, cooled rapidly to room

temperature and dried in an oven for 12 hours or more.

The dried solid dispersed preparation was milled in a mortar and passed through a sieve to give a powder which was uniform in particle size.

5

EXAMPLE I

In 5 g of oleic acid were homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added into 85 g of PEG 6000 which was molten at about 70 °C. After being cooled rapidly to room temperature and dried in an oven for 12 hours or more, the dried solid dispersed preparation was milled in a mortar and passed through a sieve to give a powder which was uniform in particular size.

15

EXAMPLE II

In 5 g of oleic acid and 5 g of Tween 80 were homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

25

EXAMPLE III

In 5 g of isopropyl myristate was homogeneously mixed

and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

5

EXAMPLE IV

In 5 g of liquid paraffin was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE V

15

In 5 g of cremophor was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE VI

In 5 g of cremophor and 5 g of Tween 80 was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was

obtained in the same procedure as in Example I.

EXAMPLE VII

5 In 5 g of isopropyl myristate and 5 g of Tween 80 was
homogeneously mixed and dispersed 10 g of ketoconazole
which was, then, added in 80 g of PEG 6000 which was molten
at about 70 °C. Using this mixture, a dispersed powdery
preparation was obtained in the same procedure as in Example
10 I.

EXAMPLE VIII

15 In 5 g of liquid paraffin and 5 g of Tween 80 was
homogeneously mixed and dispersed 10 g of ketoconazole
which was, then, added in 80 g of PEG 6000 which was molten
at about 70 °C. Using this mixture, a dispersed powdery
preparation was obtained in the same procedure as in Example
I.

20

EXAMPLE IX

25 In a microemulsion containing 5 g of cremophor, 5 g of
oleic acid, 35 g of alcohol and 1 g of transcitol was
homogeneously dissolved and dispersed 10 g of ketoconazole,
followed by evaporating the alcohol. The solid residue was,
then, added in 43 g of PEG 6000 molten at about 70 °C.

Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE X

5

In a microemulsion containing 5 g of cremophor, 5 g of oleic acid and 1 g of transcutool was dissolved 10 g of ketoconazole which was, then, dispersed in 35 g of distilled water, followed by evaporating the distilled water in an oven. The solid residue was added in 43 g of PEG 6000 molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

15

EXAMPLE XI

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of ketoconazole. 40 g of hydroxypropylmethylcellulose, an enteric matrix, was added in 40 g of PEG 6000 molten at 70 °C. Using the mixture of the above two solutions, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE XII

25

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of itraconazole which was, then, added in 80

g of PEG 6000 which was molten at 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

5

EXAMPLE XIII

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of itraconazole. 40 g of hydroxypropylmethylcellulose, an enteric matrix, was added in 40 g of PEG 6000 which was molten at 70 °C. Using the mixture of the above two solutions, a dispersed powdery preparation was obtained in the same procedure as in Example I.

15

EXAMPLE XIV

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of an itraconazole derivative (Dong-A Pharmacy Co., Ltd., Korea) which was, then, added in 80 g of PEG 6000 which was molten at 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

25

EXAMPLE XV

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of cyclosporine which was, then, added in 80

g of PEG 6000 which was molten at 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

5

EXAMPLE XVI

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of cyclosporine. 40 g of hydroxypropylmethylcellulose, an enteric matrix, was added in 40 g of PEG 6000 which was molten at 70 °C. Using the mixture of the above two solutions, a dispersed powdery preparation was obtained in the same procedure as in Example I.

15

EXAMPLE XVII

In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of cisapride which was, then, added in 80 g of PEG 6000 which was molten at 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

25

EXAMPLE XVIII

In 5 g of oleic acid and 5 g of Tween 80 was homogeneously mixed and dispersed 10 g of cisapride which was, then, added in 80 g of PEG 6000 which was molten at 70

°C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE XIX

5

In a microemulsion containing 10 g of cremophor, 5 g of oleic acid and 7 g of transcitol was homogeneously dissolved and dispersed 10 g of itraconazole, followed by evaporating the alcohol in an oven. The solid residue was, then, added in 43 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE XX

15

In a microemulsion containing 10 g of cremophor, 4 g of captex and 5 g of transcitol was homogeneously dissolved and dispersed 10 g of cyclosporine, followed by evaporating the alcohol in an oven. The solid residue was, then, added in 43 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

EXAMPLE XXI

25

In a microemulsion containing 10 g of cremophor, 5 g of oleic acid and 7 g of transcitol was homogeneously

dissolved and dispersed 10 g of cisapride, followed by evaporating the alcohol in an oven. The solid residue was, then, added in 43 g of PEG 6000 which was molten at about 70 °C. Using this mixture, a dispersed powdery preparation
5 was obtained in the same procedure as in Example I.

EXAMPLE XXII

In 5 g of oleic acid was homogeneously mixed and
10 dispersed 10 g of ketoconazole which was, then, added in 80 g of molten PVP. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

15 EXAMPLE XXIII

In a microemulsion containing 5 g of oleic acid was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of molten PVP. Using this
20 mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.

COMPARATIVE EXAMPLE II

25 After being melted at about 70 °C, 2.5 g of molten PEG 6000 was added with 1.75 g of aceclofenac, cooled rapidly to room temperature and dried in a freeze-drier for 24 hours or

more. The dried solid dispersed preparation was finely milled in a grinder and passed through a sieve to give a powder which was uniform in particle size.

5

EXAMPLE XXIV

In 0.25 g of oleic acid and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac, and then, the solution was added in 2.5 g of PEG 6000 which was molten at about 75 °C. After being cooled rapidly to room temperature

And dried in a freeze-drier for 24 hours or more, the dried solid dispersed preparation was finely milled in a grinder and passed through a sieve to give a powder which was uniform in particle size.

15

EXAMPLE XXV

In 0.25 g of cemophor and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac which was, then, added in 2.5 g of PEG 6000 which was molten at about 75 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example XXIV.

25

EXAMPLE XXVI

In 0.25 g of labrasol and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac which was, then, added in 2.5 g of PEG 6000 molten at about 75 °C. Using this mixture, a dispersed powdery preparation
5 was obtained in the same procedure as in Example XXIV.

EXAMPLE XXVII

In 0.25 g of transcitol and 0.50 g of Tween 80 was
10 homogeneously mixed and dispersed 1.75 g of aceclofenac which was, then, added in 2.5 g of PEG 6000 molten at about 75 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example XXIV.

EXAMPLE XXVIII

15

A mixture of 10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween 80, 5 g of talc and 10 g of PEG 6000 was heated at about 80 °C and homogeneously dispersed in 150 ml of an
20 alcohol. With the aid of a fluid bed-coating machine (nozzle; 0.8 mm), the resulting solution was sprayed at a rate of 4 ml/min onto 35 g of sugar spheres to give a solid dispersed granule.

EXAMPLE XXIX

25

10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween

80, 3 g of talc, 25 g of Eudragit (Rhompharm, Germany) RS30D
and 25 g of Eudragit L30D were homogeneously mixed. With
the aid of a fluid bed-coating machine (nozzle; 0.8 mm), the
resulting solution was sprayed at a rate of 4 ml/min onto 35
5 g of the sugar spheres prepared in Example XXVIII.

EXAMPLE XXX

10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween
10 80, 3 g of talc and 50 g of Eudragit RS30D were homogeneously
mixed. With the aid of a fluid bed-coating machine (nozzle;
0.8 mm), the resulting mixture was sprayed at a rate of 4
ml/min onto the sugar spheres prepared in Example XXVIII.

EXAMPLE XXXI

15 A mixture of 2.5 g of cisapride, 2.5 g of oleic acid,
2.5 g of Tween 80, 5 g of talc and 23 g of PEG 6000 was heated
at about 80 °C and added with 150ml of a mixture of acetone
20 and water (acetone:water, 1:1). With the aid of a fluid
bed-coating machine (nozzle; 0.8 mm), the resulting mixture
was sprayed at a rate of 4 ml/min onto 100 g of sugar spheres.

EXAMPLE XXXII

25 2.5 g of cisapride, 2.5 g of oleic acid, 2.5 g of Tween
80, 3 g of talc, 25 g of Eudragit RS30D and 25 g of Eudragit

L30D were homogeneously mixed in 150ml of acetone. With the aid of a fluid bed-coating machine (nozzle; 0.8 mm), the resulting mixture was sprayed at a rate of 4 ml/min onto 70 g of the sugar spheres prepared in Example XXXI.

5

EXAMPLE XXXIII

Aceclofenac, lactose, starch and talc were mixed to give a tablet in accordance with the established method.
10 2.5g of aceclofenac, 2.5g of oleic acid, 2.5g of tween 80, 3g of talc, 25g of Eudragit RS30D and 25g of Eudragit L30D were homogeneously mixed. With the aid of a fluid bed-coating machine (nozzle; 0.8mm), the resulting mixture was sprayed at a rate of 4ml/min onto the said tablets to obtain
15 a solid dispersed tablet.

EXAMPLE XXXIV

Cisapride, lactose, starch and talc were mixed to give
20 a tablet in accordance with the established method. 2.5g of cisapride, 2.5g of oleic acid, 2.5g of tween 80, 25g of Eudragit RS30D and 25g of Eudragit L30D were homogeneously mixed. With the aid of a fluid bed-coating machine (nozzle; 0.8mm), the resulting mixture was sprayed at a rate
25 of 4ml/min onto the said tablets to obtain a solid dispersed tablet.

EXPERIMENT I : The Drug Solubility of Solid Dispersed Preparation In Water and Artificial Intestinal Juice

In this experiment, the solubility of poorly water-soluble drugs in water and artificial intestinal juice was investigated for the solid preparations obtained in Comparative Example and Examples. In this regard, suspensions of 2 g of the solid dispersion preparations of this invention in water or artificial intestinal juice were
10 filtrated through a 0.2 μ m filter paper (Millipore, Waters, Milford, MA, USA) and the filtrate was diluted for the convenient quantification of the drugs. The solubility results are given in Table 1.

15

TABLE 1

Solubility of Ketoconazole in distilled water and artificial intestinal juice

Solid Dispersed Preparatio	Solubility (μ g/mP)	
	DI-Water	Artificial Intestinal Juice
Ketoconazole Powder	0.10	2.08
Comparative Example	3.77	-
Example I	41.4	44.8
Example II	73.9	-
Example III	2.47	-
Example IV	2.28	-
Example V	8.02	-

Example VI	12.0	-
Example VII	6.31	-
Example VIII	12.2	-
Example IX	72.8	50.7
Example X	63.6	37.8

As apparent from the data of Table 1, the solubility of the drugs in distilled water was significantly improved when they were incorporated in solid dispersed preparations containing oleic acid. Particularly, the drugs in the solid dispersed preparations prepared from microemulsions containing oleic acid showed a great advance in the solubility in water as well as in artificial intestinal juice.

10

EXPERIMENT II: The drug-releasing Rate of Solid Dispersed Preparations in Artificial Gastric and Intestinal Juices

The solid dispersed preparations comprising ketoconazole or cisapride, respectively, obtained in Examples, were tested for releasing rates in artificial gastric juice and artificial intestinal juice.

According to the paddle process described in Korean Pharmacopoeia VI (KP VI), this releasing test was carried out in artificial gastric juice and artificial intestinal juice at 37 ± 0.5 °C while the paddle was rotated at 50 rpm.

At an interval of a predetermined period of time, samples were taken from the artificial juices and filtered through 0.2 μ m Millipore paper and the filtrates were measured for plasma concentration of drug. The releasing levels and percentages of the poorly water-soluble drugs against artificial gastric and intestinal juices are given in Tables 2 and 3.

TABLE 2

10 Releasing Level (μ g/ml) and Percentage (%) of Poorly water-soluble Drugs in Artificial Gastric Juice

Prep.	Time (hours)								
	0.25	0.5	0.75	1.0	1.5	2.0	3.0	4.0	6.0
Keto. Powder	432 (72.0)	437 (72.8)	436 (72.7)	436 (72.6)	434 (72.4)	439 (73.2)	437 (72.7)	435 (72.5)	437 (72.7)
Exmp. I	46.7 (95.9)	49.4 (101.5)	50.5 (103.8)	50.8 (104.3)	50.8 (104.3)	50.6 (104.1)	50.4 (103.6)	50.5 (103.7)	50.5 (103.8)
Exmp. II	49.5 (108.9)	51.6 (113.5)	52.7 (115.9)	53.1 (116.9)	53.5 (117.7)	53.4 (117.4)	52.9 (116.4)	82.9 (116.4)	53.0 (116.6)
Exmp. III	51.6 (107.5)	51.6 (107.6)	52.7 (109.9)	53.1 (110.8)	53.5 (111.6)	53.8 (112.2)	53.0 (110.6)	53.4 (111.3)	53.0 (110.7)
Exmp. IV	51.7 (112.3)	51.4 (111.8)	51.4 (111.7)	51.2 (111.3)	51.6 (112.2)	52.0 (113.0)	51.5 (111.9)	50.9 (110.6)	51.8 (112.6)
Exmp. V	50.3 (111.5)	50.9 (112.7)	50.4 (111.7)	50.7 (112.3)	50.9 (112.7)	50.8 (112.4)	50.8 (112.4)	60.0 (112.9)	50.7 (112.3)
Exmp. VI	45.8 (99.0)	46.3 (100.0)	46.2 (99.8)	46.2 (99.9)	46.2 (99.9)	45.8 (98.9)	45.6 (98.5)	45.1 (97.5)	45.8 (99.1)
Exmp. VII	48.8 (100.4)	48.8 (100.4)	48.9 (100.4)	48.9 (100.6)	49.0 (100.9)	49.9 (102.5)	49.9 (102.7)	50.2 (103.2)	50.1 (102.9)
Exmp. VIII	46.5 (104.3)	45.8 (102.2)	45.9 (102.9)	45.5 (102.1)	46.4 (104.2)	46.4 (104.1)	45.8 (102.8)	45.3 (101.7)	45.6 (102.3)
Cisa- pride Powder	-	5.249 (51.57)	-	5.492 (54.51)	5.914 (58.63)	6.243 (61.81)	6.173 (61.22)	-	6.446 (65.80)

Exmp. XVII	-	8.93 (95.27)	-	8.74 (84.09)	9.12 (87.9)	8.79 (84.54)	9.13 (87.81)	-	9.30 (89.47)
Exmp. XVIII	-	9.94 (103.2)	-	9.74 (102.1)	10.03 (105.2)	9.93 (104.3)	9.76 (102.4)	-	9.68 (101.5)

As shown in Table 2, ketoconazole, although it can be released in the artificial gastric juice to an extent because of its acidic property, is relatively further improved in the releasing level and percentage when it is incorporated in the oleic acid-containing solid dispersed preparations. Therefore, these data are consistent with those of Experiment I. In the meanwhile, cisapride was released to an extent by virtue of its solubility, but also considerably increased in the releasing properties when it was used in the solid dispersed preparations of the present invention.

TABLE 3

Releasing Level ($\mu\text{g/ml}$) and Percentage (%) of Poorly water-soluble Drugs in Artificial Intestinal Juice

Prep.	Time (hours)								
	0.25	0.5	0.75	1.0	1.5	2.0	3.0	4.0	6.0
Ketoco azole Powder	1.84 (0.092)	1.89 (0.095)	1.91 (0.096)	1.92 (0.096)	1.94 (0.97)	1.99 (0.099)	1.98 (0.099)	2.05 (0.103)	2.08 0.104
C. Exmp	3.05 (4.99)	3.38 (5.53)	3.69 (6.05)	3.71 (6.08)	3.75 (6.14)	3.84 (6.29)	3.87 (6.33)	3.87 (6.34)	4.32 (7.08)
Exmp. I	4.89 (10.05)	5.14 (10.56)	5.68 (11.67)	5.80 (11.91)	5.17 (10.61)	5.2 (10.68)	5.2 (10.68)	5.32 (0.92)	6.00 (12.33)
Exmp.	3.55	3.61	3.71	3.96	3.7	3.97	4.09	4.11	4.29

II	(7.82)	(7.94)	(8.15)	(8.75)	(8.13)	(8.73)	(8.98)	(9.04)	(9.42)
Exmp. III	1.44 (3.00)	1.45 (3.04)	1.46 (3.05)	1.67 (3.47)	1.77 (3.69)	1.92 (3.99)	1.95 (4.06)	2.14 (4.47)	2.36 (4.92)
Exmp. IV	1.03 (2.23)	1.27 (2.76)	1.31 (2.84)	1.36 (2.95)	1.45 (3.15)	1.48 (3.21)	1.57 (3.41)	1.63 (3.54)	1.69 (3.67)
Exmp. V	2.21 (4.89)	2.23 (4.94)	2.21 (5.03)	2.27 (5.10)	2.31 (5.15)	2.33 (5.46)	2.47 (5.26)	2.38 (5.34)	2.40 (5.30)
Exmp. VI	2.78 (6.00)	2.53 (5.47)	2.42 (5.23)	2.54 (5.49)	2.19 (4.72)	2.41 (5.21)	2.3 (4.97)	2.34 (5.06)	2.45 (5.29)
Exmp. VII	2.09 (4.28)	2.03 (4.16)	2.1 (4.31)	2.20 (4.51)	2.07 (4.26)	2.2 (4.52)	2.16 (4.43)	2.08 (4.26)	2.08 (4.26)
Exmp. VIII	2.26 (5.07)	2.51 (5.61)	2.42 (5.42)	2.64 (5.92)	2.58 (5.77)	2.57 (5.76)	2.42 (5.41)	2.52 (5.64)	2.59 (5.81)
Exmp. IX	3.55 (10.70)	3.95 (11.89)	4.12 (12.41)	4.27 (12.86)	4.28 (12.88)	4.34 (13.08)	4.38 (13.19)	4.38 (13.20)	4.36 (13.13)
Exmp. X	2.37 (6.75)	2.48 (7.05)	2.39 (6.79)	2.14 (6.08)	2.78 (7.92)	2.67 (7.60)	3.42 (9.72)	3.61 (10.27)	3.63 (10.33)
Cisa- pride Powder	-	0 (0)	-	0 (0)	0 (0)	0 (0)	0.005 (0.047)	0.028 (0.27)	0.0745 (0.618)
Exmp. XVII	-	2.43 (20.15)	-	3.22 (26.7)	2.70 (22.42)	2.66 (22.1)	2.64 (21.94)	3.10 (25.73)	3.99 (33.12)
Exmp. XVIII	-	6.34 (63.0)	-	6.75 (67.01)	6.56 (65.15)	6.55 (65.05)	6.69 (66.46)	6.74 (66.9)	6.96 (69.05)

The effect of the solid dispersed preparations on improving the releasing rates of the two drugs is more apparent in the artificial intestinal juice, a more
5 difficult condition in which for the two drugs to dissolve.

As shown in Table 3, the releasing properties of drugs are better when they are incorporated in the solid dispersed preparations using fatty acid and oil than when they are used alone. A better improvement effect was obtained from
10 the solid dispersed preparations containing oleic acid.

Further, the use of microemulsified oleic acid brought

about a great advance in the releasing properties.

In addition, the solid dispersed preparations containing itraconazole, its derivatives, and cyclosporine, respectively, was tested for the releasing properties in the artificial gastric and intestinal juices. The results are given in Table 4. Also, the data of Table 4 demonstrate that the drugs in the solid dispersed preparations are superior to the drugs alone in the releasing properties.

10

TABLE 4

Releasing Level ($\mu\text{g/ml}$) of Poorly water-soluble Drugs in Artificial Gastric and Intestinal Juice

Prep.	Time (Min)											
	Artificial Gastric Juice						Artificial Intestinal Juice					
	5	15	30	60	90	120	5	15	30	60	90	120
Itra ¹	14.4	16.4	17.4	16.7			0.05	0.05	0.05	0.05	-	-
Exmp.XII	292	293	321	331			130	95.0	146	102	-	-
Exmp.XIII	138	160	179	192			246	214	204	203	-	-
Itra Drv. ²	96.9	156.2	189.2	211.0	216.7		-	-	-	-	-	-
Exmp.XIV	204.5	198.6	232.6	252.9	259.8		-	-	-	-	-	-
Cyclo. ³	-	-	1.8	1.7	-	1.9	-	-	2.1	2.3	-	2.5
Exmp.XV	-	-	111.4	94.8	-	71.7	-	-	102.8	99.4	-	91.0
Exmp.XVI	-	-	11.1	10.8	-	9.8			595.0	66.3	-	56.7

¹ Itrakonazole powder

² Itrakonazole derivative

15 ³ Cyclosporine

EXPERIMENT III: Uptake of Poorly water-soluble Drugs in

Rabbit 's Gastrointestinal tract

The solid dispersed preparations containing ketoconazole, prepared from Examples, were tested for the uptake in rabbit's gastrointestinal tract. The results are given in Table 5.

In this regard, first, a rabbit was killed by introducing air in its ear vein and its stomach, duodenum, jejunum, ileum, colon and rectum were excised and washed with physiological saline solution at 37 °C. These organs were fixed between the receptor and donor of a Franz diffusion cell. In the receptor, a physiological saline solution warmed to 37 °C was poured, and stirred with a magnetic stirrer while the solid dispersed preparations obtained in Examples were added in the donor. Samples were harvested from the receptor at predetermined times for 6 hours while the receptor was supplemented with a fresh physiological saline solution in order to constantly maintain the total volume in the receptor. The samples taken were measured for their plasma concentrations of drugs.

TABLE 5

Uptake ($\mu\text{g}/\text{cm}^2$) of Ketoconazole in Rabbit's GI tract

Prep.	Time (hours)							
	0.3	0.67	1	1.5	2	3	4	6
C. Exmp	0	0.92	2.45	4.50	4.67	5.15	5.56	5.95

Exmp. I	0	1.72	3.44	5.46	9.10	10.2	11.6	13.2
Exmp. II	0.50	2.78	5.50	9.83	15.5	16.3	18.6	22.4

It is apparent from the data of Table 5 that the uptake of the drug in the GI tract is much better when it is incorporated in the solid dispersed preparation using oleic acid than when it is incorporated in the conventional dispersed preparation which uses a water-soluble matrix merely. Particularly, a significant improvement in the uptake of ketoconazole in the GI tract was brought about by the use of the solid dispersed preparations obtained from microemulsions containing oleic acid. These results are consistent with those of Experiment I and II.

EXPERIMENT IV: Comparison of the Plasma Concentration of Drugs Formulated into a Solid Dispersed Preparation and Commercially Available Ones

Before an experiment, male mice (Sprague-Dawley lineage) weighing 250-310 g, purchased from the Korea National Institute of Health, were adapted to new circumstances for 1-2 weeks. After the mice, which were starved from one day before the experiment, were etherized, their left femoral arteries were inserted with cannulas connected to syringes containing 80 IU/ml of heparin. After 2 hours, the mice came out of the ether and were administered with a suspension of the cyclosporine-

containing solid dispersed preparation of the present invention and a commercially available preparation with the aid of a sonde. At an interval of a predetermined period of time, blood was taken from the left femoral arteries and
5 measured for the plasma concentration of drug.

With reference to Fig. 1, the cyclosporine level in blood are plotted against the times after administration for the solid dispersed preparations of the present invention and a commercially available preparation. As
10 shown in the graph, the plasma concentration of the solid dispersed preparations according to the present invention are similar to that of the commercially available preparation, Neoral. Although being a little bit lower concentration than that of Neoral as a whole, the solid
15 dispersed preparations according to the present invention are thought to have the initiatives to substitute for the conventional preparations which contain liquid drugs, in a pharmaceutical aspect.

Solid dispersed preparations according to the present
20 invention and a commercial available preparation, all containing itraconazole as a medicinally effective ingredient, were administered to beagle dogs in an oral route. After a blood sample was taken from their veins at an interval of a predetermined period of time, the plasma
25 concentration of drug was measured. The results are given in Table 6.

TABLE 6

Itraconazole Level ($\mu\text{g/ml}$) in Blood According to Times

Prep.		Time (hours)							
		1	2	3	4	6	8	10	24
Starved Dog	Exmp. XII	0	0.03	0.03	0.04	0.03	0.02	0.02	0.02
	Exmp. XIII	0.02	0.06	0.07	0.08	0.10	0.07	0.04	0.03
	Purchased	0	0.06	0.04	0.03	0.09	0.03	0.06	0.03
Non-starved	Exmp. XIII	0.12	0.41	0.38	0.44	0.43	0.43	0.42	0.36
	Purchased	0.30	0.60	0.79	0.58	0.54	0.44	0.41	0.30

As apparent from Table 6, a similar pharmacokinetic pattern was observed between the plasma concentration of itraconazole from the solid dispersed preparations and from the conventional preparation (itazol) when starved beagle dogs were administered therewith, while the lower value shown in case the preparation of Examp. XII was administered. In non-starved beagle dogs, the drug reached a high maximal level in blood within a fast period of time when the commercially available preparation was administered whereas the preparation of Example XIII maintained the plasma concentration of drug constantly, owing to its solubilization in the gastro-intestinal tract.

EXPERIMENT V: Solubility of Aceclofenac in Various Vehicles

Excess aceclofenac was added in 5 ml of a vehicle in a test tube, which was then vortexed to an extent that the drug

was not dissolved further, and incubated for 3 days in a 37 °C water bath. The resulting solution was filtrated through a 0.2 µm filter paper (Millipore, Waters, Milford, MA, USA) and the filtrate was diluted for the convenient
5 quantification of the drug. The solubility results are given in Table 7.

Table 7

Solubility of Aceclofenac in Vehicles

Vehicles	Solubility (mg/mP)
Transcutol	149.34
Labrasol	114.83
Tween 80	98.70
Tween 20	85.71
Cremophor EL	40.92
Cremophor RH40	23.34
Oleic acid	4.59
Linoleic acid	5.44
Triacetin	18.01
Castor oil	13.21
Sesame oil	2.83
Corn oil	2.20
Mineral oil	0.34

10

As apparent from the data of Table 7, large values are found in the solubility of aceclofenac in fatty acids, triacetin, castor oil and cremophor. Particularly, the drug is dissolved at great amounts in transcutol, labrasol
15 and Tweens.

EXPERIMENT VI: Releasing of Aceclofenac in Solid Dispersed Preparations Against Artificial Gastric and Intestinal

Juices

The solid dispersed preparations comprising aceclofenac, obtained in Examples XXIV to XXVII, were tested for releasing properties against artificial gastric juice and artificial intestinal juice in a similar manner to that of Experimental Example II.

The releasing levels and percentages of the poorly water-soluble drugs against artificial gastric and intestinal juices are given in Tables 8 and 9.

Table 8
Releasing Level ($\mu\text{g/ml}$) and Percentage (%) of
Aceclofenac in Artificial Gastric Juice

Prep.	Time (hours)						
	0.25	0.5	0.75	1.0	1.5	2.0	3.0
Aceclofenac Powder	0.46 (0.23)	0.53 (0.26)	0.57 (0.28)	0.60 (0.30)	0.61 (0.31)	0.69 (0.34)	0.73 (0.37)
Exmp. XXIV	1.01 (0.51)	1.16 (0.58)	1.29 (0.65)	1.33 (0.67)	1.35 (0.67)	1.43 (0.72)	1.38 (0.69)
Exmp. XXV	1.68 (0.84)	2.38 (1.19)	2.43 (1.22)	2.51 (1.25)	2.68 (1.34)	2.65 (1.33)	2.70 (1.35)
Exmp. XXVI	1.61 (0.80)	1.88 (0.94)	1.96 (0.98)	1.98 (0.99)	1.99 (1.10)	1.95 (0.98)	2.08 (1.04)
Exmp. XXVII	1.76 (0.88)	2.04 (1.02)	2.36 (1.18)	2.51 (1.26)	2.61 (1.30)	2.70 (1.35)	2.63 (1.31)
Airtal	0.93 (0.46)	1.02 (0.51)	1.18 (0.59)	1.23 (0.61)	1.32 (0.66)	1.34 (0.67)	1.39 (0.70)

15

As shown in Table 8, the releasing of aceclofenac in the artificial gastric juice was much improved when it was

in the solid dispersed preparations of the present invention relatively to the other preparations.

TABLE 9

5 Releasing Level ($\mu\text{g/ml}$) and Percentage (%) of
 Aceclofenac in Artificial Intestinal Juice

Prep.	Time (hours)							
	0.25	0.5	0.75	1.0	1.5	2.0	3.0	5.0
Aceclo. Powder	88.37 (44.19)	117.34 (58.67)	121.65 60.82	126.64 (63.32)	128.10 (64.05)	131.70 (65.85)	136.55 (68.27)	136.55 (68.28)
Exmp. XXIV	152.97 (76.49)	157.43 (78.72)	161.90 80.95	160.40 (80.20)	162.66 (81.33)	164.09 (82.05)	165.27 (82.63)	166.71 (83.35)
Exmp. XXV	151.72 (75.86)	163.33 (81.67)	161.72 80.86	163.11 (81.55)	162.26 (81.13)	165.57 (82.79)	166.16 (83.08)	166.16 (83.08)
Exmp. XXVI	148.21 (74.10)	152.40 (76.20)	154.58 77.29	154.95 (77.47)	154.49 (77.24)	155.48 (77.74)	157.97 (78.99)	159.74 (79.87)
Exmp. XXVII	138.83 (69.41)	150.41 (75.21)	155.85 77.92	161.51 (80.75)	161.63 (80.81)	163.29 (81.64)	164.22 (82.11)	167.36 (83.68)
Airtal	133.76 (66.88)	136.54 (68.27)	136.62 68.31	137.70 (68.85)	142.55 (71.28)	145.72 (72.86)	143.66 (71.83)	142.34 (71.17)

As known from Table 9, aceclofenac, although it can be released in the artificial gastric juice to an extent
 10 because of its basic property, is relatively further improved in the releasing level and percentage when it is formulated into the solid dispersed preparation.

EXPERIMENT VII: Comparison of Plasma Concentration of
 15 Aceclofenac Between Solid Dispersed Preparation and Conventional Ones

Before an experiment, male mice (Sprague-Dawley lineage) weighing 250-310 g, purchased from the Korea National Institute of Health, were adapted to new circumstances for 1-2 weeks. After the mice, which were
5 starved from one day before the experiment, were etherized, their left femoral arteries were inserted with cannulas connected to syringes containing 50 IU/ml of heparin. After 2 hours, the mice came out of the ether and were administered with a suspension of the aceclofenac-
10 containing solid dispersed preparation of the present invention and a aceclofenac powder with the aid of a sonde. At an interval of a predetermined period of time, blood was taken from the left femoral arteries and measured for the plasma concentration of the drug.

15 In the meanwhile, the aceclofenac-carrying solid dispersed preparations of the present invention and a commercial available preparation were orally administered to beagle dogs and volunteers. At predetermined times after oral administration, blood was taken from the beagle
20 dogs and the volunteers and measured for the drug levels.

After the oral administration of the aceclofenac-carrying solid dispersed preparations of the present invention, an aceclofenac powder and a commercial available preparation to mice, beagles dogs and volunteers, the
25 plasma concentration of the drug with time were compared and are plotted in Figs. 2 to 4.

As shown in the graphs, the solid dispersed preparations of

the present invention maintain higher levels of aceclofenac in blood for all of the testees than the commercially available preparation. In addition, the use of the solid dispersed preparation according to the present invention was affirmed to increase the maximal value of plasma concentration and area under the curve, which are pharmacokinetic parameters, by 1.5-6 times.

After the oral administration of the aceclofenac-carrying solid dispersed preparation of the present invention, a commercially available preparation and an aceclofenac powder, the plasma concentration of aceclofenac was monitored with time and the results are given in Tables 10 to 12, below.

15

TABLE 10

Aceclofenac Level ($\mu\text{g/ml}$) in Blood of Rat

Prep.	Time (hours)								
	0.25	0.5	0.75	1	1.5	2	3	4	6
Exmp. XXIV	11.11	14.30	12.96	8.01	4.45	3.38	2.60	0.70	0.85
Aceclo. Powder	1.85	0.71	0.44	0.15	0.03	0.16	0.21	0.27	0.13

It is apparent from the data of Table 10 that the aceclofenac level in blood is significantly improved when the drug is administered by use of the preparation of the present invention relative to when aceclofenac is administered alone.

TABLE 11

Plasma Concentration ($\mu\text{g/ml}$) of Aceclofenac
in Beagle Dogs

Prep.	Time (hours)											
	0.25	0.5	0.75	1	1.5	2	3	5	7	9	12	24
Exmp. XXIV	4.9	41.1	74.1	81.8	93.0	96.5	71.1	49.4	32.2	21.6	11.1	1.3
Airtal	4.6	15.1	28.9	35.7	50.8	43.2	31.9	16.6	8.8	6.4	3.9	0.8

The data of Table 11 demonstrate that the
5 aceclofenac-carrying solid dispersed preparation of the
present invention is superior to the conventional
preparation in the plasma concentration.

TABLE 12

10 Plasma Concentration ($\mu\text{g/ml}$) of Aceclofenac
in Human Blood

Prep.	Time (hours)										
	0.25	0.5	0.75	1	1.5	2	3	5	7	9	12
Exmp. XXIV	0.16	4.67	10.98	18.12	12.99	6.93	2.97	1.02	0.67	0.56	0.42
Airtal	0.85	1.75	3.84	5.51	5.48	8.34	3.44	0.48	0.29	0.14	0.10

As apparent from the data of Table 12, higher levels of
aceclofenac in blood are maintained when the solid
15 dispersed preparation of the present invention is
administered than when the commercially available
preparation is used.

EXPERIMENT VIII: Releasing of Cisapride From Solid

Dispersed Preparations Against Artificial Gastric and Intestinal Juices

The solid dispersed preparation comprising cisapride, obtained in Examples XXXI, was tested for releasing properties against artificial gastric juice and artificial intestinal juice in a similar manner to that of Experimental Example II.

The releasing levels and percentages of the poorly water-soluble drugs against artificial gastric and intestinal juices are given in Table 13.

TABLE 13

Releasing Level ($\mu\text{g/ml}$) and Percentage (%) of Cisapride in Artificial Gastric and Intestinal Juice

Juice	Time (hour)									
	0.5	1.0	1.5	2.0	3.0	4	5	6	8	12
Gastric	14.9	26.2	32.0	43.4	58.5	-	84.7	-	-	-
Intestina	8.1	16.5	25.2	38.1	48.5	62.1	-	72.7	87.8	98.0

The amount of the drug released from the solid dispersed preparation was increased almost linearly in both artificial gastric and intestinal juices, showing a zero order-like kinetics.

EXPERIMENT IX: Comparison of Plasma Concentration of

Cisapride Between Solid Dispersed Preparation and Commercially Available Ones

- At an interval of a predetermined period of time after
the oral administration of beagle dogs with the
cisapride-carrying solid dispersed preparation obtained in
Example XXXII and a commercially available preparation,
blood was taken from the testees and measured for plasma
concentration of drug.
- With reference to Fig. 5, the cisapride levels in blood are
plotted against the times after administration for the
solid dispersed preparations of the present invention and a
commercially available preparation, Prepulsid tablet. As
shown in the graph, the plasma concentration of the solid
dispersed preparations according to the present invention
are greatly improved relative to that of the commercially
available preparation. These drug concentrations are
numerically shown in Table 14, below.

20

TABLE 14

Plasma Concentration of Cisapride ($\mu\text{g/ml}$)
in Beagle Dog

Prep.	Time (hours)											
	0.5	0.75	1	1.25	1.5	2	3	5	7	9	12	24
Exmp. XXXII	48	80	68	82	97	151	271	284	152	104	83	63
Prepulsid	49	61	70	83	102	184	201	134	75	58	46	41

As shown in Table 14, the plasma concentration of cisapride is maintained at higher levels when the solid dispersed preparation of the present invention is used than when the conventional preparation.

5

As described hereinbefore, the solid dispersed preparations of the present invention are improved in the solubility of poorly water-soluble drugs in the gastrointestinal tract, in detail, the releasing of the drugs against the gastric and intestinal juices, resulting in a great increase in the bioavailability of the drugs. In addition, the solid dispersed preparations of the present invention give the pharmaceutical solutions to the problems that the conventional semi-solid or liquid preparations possess, enabling medicinally effective, poorly water-soluble compounds to be formulated, molded and processed, quickly and in an economically favorable manner without use of any organic solvent.

The present invention has been described in an illustrative manner, and it is to be understood the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

WHAT IS CLAIMED IS:

1. A solid dispersed preparation for poorly water-soluble drugs, prepared by dissolving or dispersing the drugs in
5 an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture.
2. The solid dispersed preparation as set forth in claim
10 1, wherein the solid dispersed preparation is obtained by pulverizing the dried mixture to give a dispersed powdery preparation.
3. The solid dispersed preparation as set forth in claim
15 1, wherein the mixture is dried in such a way that the mixture is sprayed to pharmaceutically acceptable nuclei to give a dispersed granular preparation.
4. The solid dispersed preparation as set forth in claim
20 1, wherein the oil, the fatty acid or the mixture thereof is used in a form of an emulsion or a micro emulsion.
5. The solid dispersed preparation as set forth in claim
25 1, wherein the oil is selected from the group comprising α -bisabolol, stearyl glycerphosphate, salicylic acid, tocopheryl acetate, sodium hyaluronate, panthenol, propylene glycol and apple (*Pirus Malus*), propylene

glycol and pineapple, ivy (*Hedera helix*) extract and
 1,3-B.G, peach (*Prunus persica*) leaf extract, hydrolyzed
 soy flour, wheat (*Triticum Vulgare*) protein, birch
 (*Betula alba*) extract and 1,3-B.G, burdock (*Arctium*
 5 *majus*) extract and 1,3-B.G, liposomes,
 phosphatidylcholines, glyceryl stearate,
 caprylic/capric triglyceride, cetyl octanoate,
 isopropyl myristate, 2-ethylene isopelargonate, di-C12-
 13 alkyl malate, cetearyl octanoate, butylene glycol
 10 dicaprylate/dicaprate, isononyl isostearate,
 isostearyl isostearate, coco-caprylate/caprate, cetyl
 octanoate, octyldodecyl myristate, cetyl esters, C10-30
 cholesterol/lanosterol ester, hydrogenated castor oil,
 monoglycerides, diglycerides, triglycerides, beeswax,
 15 canauba wax, sucrose distearate, PEG-8 beeswax, ceresin,
 ozokerite, macadamia ternifolia nut oil, hydrogenated
 hi-erucic acid rape seed oil, olive oil, jojoba oil,
 hybridsunflower (*Helianthus annuus*) oil, and dog rose
 (*rosa canina*) lips oil.

20

6. The solid dispersed preparation as set forth in claim
 5, wherein the oil is selected from the group comprising
 mineral oils, squalene, squalane, monoglycerides,
 diglycerides, triglycerides, medium chain glycerides,
 25 myglyol, cremophor, hydrogenated castor oil, corn oil,
 perilla oil, cotton seed oil and lipid-soluble vitamins.

7. The solid dispersed preparation as set forth in claim 1, wherein the fatty acid is selected from the group comprising oleic acid, cetyl alcohol, stearyl alcohol, stearic acid, myristic acid, linoleic acid and lauric acid.
8. The solid dispersed preparation as set forth in claim 7, wherein the fatty acid is selected from the group comprising oleic acid, linoleic acid, and isopropyl myristate.
9. The solid dispersed preparation as set forth in claim 1, wherein the water-soluble polymer matrix is selected from the group comprising polyethylene glycol (PEG), carbowax and polyvinyl pyrrolidone (PVP).
10. The solid dispersed preparation as set forth in claim 1, wherein the poorly water-soluble drugs are dissolved and dispersed in the oil, fatty acid or their mixture in the presence of a surfactant.
11. The solid dispersed preparation as set forth in claim 10, wherein the surfactant is selected from the group comprising glyceryl stearate, polysorbate 60, polysorbate 80, sorbitan trioleate, sorbitan sesquioleate, sorbitan stearate, PEG-20 glyceryl isostearate, ceteth-25, PEG-60, PEG-60 hydrogenated

castor oil, nonoxynol-15, PEG-6-decyltetradeceth-20,
dimethicone copolyol, glyceryl diisostearate, ceteth-
24, cetearyl alcohol, polyoxylethylene nonyphenyl ether,
PEG-40 hydrogenated castor oil, cetyl dimethicone
5 copolyol, polyglyceryl-3-methylglucose distearate,
PEG-100 stearate, sorbitan isostearate, sodium lauryl
glutamate, disodium cocoamphodiacetate, lauric acid
diethanolamide, coconut fatty acid diethanolamide,
N,N-bis-(2-hydroxy ethyl)-cocamide, and
10 cocoamidopropyl betain.

12. The solid dispersed preparation as set forth in claim
1, wherein the water-soluble polymeric matrix is used
alone or in combination with other water-soluble
15 matrices.

13. The solid dispersed preparation as set forth in claim
12, wherein the other water-soluble matrix is selected
from the group comprising gelatin, gum, carbohydrates,
20 celluloses, polyvinyl alcohol, polyacrylic acid,
inorganic compounds and their mixtures,
hydroxypropylmethylcellulose acetyl succinate, shellac,
zein, polyvinyl acetate phthalate, Eudragit L100,
Eudragit S100, sodium arginate, and poly-L-lysine.

25
14. The solid dispersed preparation as set forth in claim
1, wherein the poorly water-soluble drugs are selected

from the group comprising ketoconazole, itraconazole
and its derivatives, cyclosporine, cisapride,
acetaminophen, aspirin, acetylsalicylic acid,
indomethacin, naproxen, warfarin, papaverine,
5 thiabendazole, miconazole, cinnarizine, doxorubicin,
omeprazole, cholecalciferol, melphalan, nifedipine,
digoxin, benzoic acid, tryptophan, tyrosine,
phenylalanine, aztreonam, ibuprofen,
phenoxymethylpenicillin, thalidomide,
10 methyltestosterone, prochlorperazine, hydrocortisone,
dideoxypurine nucleoside, vitamin D₂, sulfonamide,
sulfonylurea, p-aminobenzoic acid, melatonin,
benzylpenicillin, chlorambucil, diazepam, digitoxin,
hydrocortisone butyrate, metronidazole benzoate,
15 tolbutamide, prostaglandin E₁ (PGE₁), fludrocortisone,
griseofulvin, miconazole nitrate, leukotriene B₄
antagonist, propranolol, theophylline, flubiprofen,
sodium benzoate, benzoic acid, riboflavin,
benzodiazepine, phenobarbital, glyburide, sulfadiazine,
20 sulfaethylthiadiazole, sodium diclofenac, aceclofenac,
phenyroin, hioridazinehydrochloride, bropiramine,
hydrochlorothiazide, fluconazole, acyclovir,
bucillamine, ciprofluoxacin, acetyl-L-carnitine,
baclofen, sodium alendronate, lovocarnitine,
25 nimodipine or nimodifine, atenolol, provastatin sodium,
lovastatin, isotretinoin, etidronate disodium,
doxifluridine, fosfomycin calcium, sotepine,

epinastine hydrochloride, carvedilol, epinastine
hydrochloride, carvedilol, fosinopril, trandolapril,
etretinate cap, metergoline, mercaptopurine,
vancomycin hydrochloride, cefixime, cefuroxim axetil,
5 dirithramycin, and dadanosin.

15. The solid dispersed preparation as set forth in claim
13, wherein the poorly water-soluble drugs are selected
from the group comprising ketoconazole, itraconazole
10 and its derivatives, cisapride, cyclosporine,
nifedipine and aceclofenac.

16. Medicines for internal use such as powders, granules,
tablets and capsules, prepared using the solid dispersed
15 preparation of claim 1.

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 99/00341

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: A 61 K 9/14, A 61 K 9/16, A 61 K 9/20, A 61 K 9/48, A 61 K 31/20, A 61 K 9/107, A 61 K 38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9006746 A1 (MEDICONTROL CORPORATION) 28 June 1990 (28.06.90) abstract; page 5, 2 nd paragraph; page 6, 1 st paragraph; claims 1-6,8,10-12,15,16,18,22,24,25,27.	1,2,4-6,10-14,16
X	US 5756450 A (HAHN et al.) 26 May 1998 (26.05.98) abstract; column 4, lines 33-40, 46-54; column 7, lines 33-51; column 9, lines 36-40; column 14, lines 30-60; column 19, lines 3-47.	1,2,4-6,9,12-16
X	JP 08-157362 A (SANKYO CO LTD) 18 June 1996 (18.06.96) (abstract) [online] [retrieved on 28 October 1999 (28.10.99)]. Retrieved from the Internet:<URL: http://12.espacenet.com/dips/viewer?PN=JP8157362&CY=at&LG=de&DB=EPD >.	1-4,10,12,16

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

28 October 1999 (28.10.99)

Date of mailing of the international search report

03 December 1999 (03.12.99)

Name and mailing address of the ISA/AT

Austrian Patent Office

Kohlmarkt 8-10; A-1014 Vienna

Facsimile No. 1/53424/200

Authorized officer

Krenn

Telephone No. 1/53424/435

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00341

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WD A1 9006746	28-06-1990	AT E 94057 CA AA 2005810 CA AA 2005810 DE CO 68909057 DE T2 68909057 EP A1 449960 EP B1 449960 JP T2 4504108 JP B4 7121858	15-09-1993 20-06-1990 21-06-1990 14-10-1993 24-03-1994 09-10-1991 08-09-1993 23-07-1992 25-12-1995
US A 5756450	26-05-1998	AT A 272/90 AT B 404552 AU A1 49252/90 AU B2 630413 BE AF 1003009 CA AA 2009533 CH A 679277 CY A 1903 DE A1 4003844 DK A0 327/90 DK A 327/90 ES AF 2021942 FI A0 900604 FI B 97524 FI C 97524 FR A1 2642650 FR B1 2642650 GB A0 8903663 GB A0 9002504 GB A1 2230440 GB B2 2230440 GR A 90100076 GR B 1000466 HK A 372/96 HU A0 900701 HU A2 54058 HU B 213394 IE B 65191 IL A0 93298 IL A1 93298 IT A0 9047609 IT A 1240758 JP A2 2235817 LU A 87675 NL A 9000299 NO A0 900577 NO A 900577 NO B1 301576 NZ A 232401 PT A 93079 PT B 93079 SE A0 9000441 SE A 9000441 SE C2 511398 GB A0 8903147 GB A0 8902901 GB A 9000993 GB A0 8902898 AT A 2249788 AT B 395819 AU A1 22172/88 AU B2 628787 BE AF 1001204 CA A1 1338775 CH A 683672 DK A0 5111/88 DK A 5111/88 ES AF 2012118 FI A0 884192 FI A 884192 FI E 94837 FI C 94837 FR A1 2620336 FR B1 2620336 GB A1 2209671 GB B2 2209671 GR A 88100602 GR B 1002243 HU A2 49494	15-05-1998 28-12-1998 16-08-1990 29-10-1992 22-10-1991 09-08-1990 31-01-1992 22-11-1996 16-08-1990 07-02-1990 10-08-1990 16-11-1991 07-02-1990 30-09-1996 10-01-1997 10-08-1990 09-12-1994 05-04-1989 04-04-1990 24-10-1990 19-05-1993 28-06-1991 30-07-1992 15-03-1996 28-04-1990 28-01-1991 30-06-1997 04-10-1995 29-11-1990 10-06-1997 08-02-1990 17-12-1993 18-09-1990 08-10-1991 03-09-1990 07-02-1990 10-08-1990 17-11-1997 28-10-1992 31-08-1990 30-04-1996 07-02-1990 08-08-1991 20-09-1999 30-03-1989 30-03-1989 30-10-1991 30-03-1989 15-08-1992 25-03-1993 27-04-1989 24-09-1992 16-08-1989 10-12-1996 29-04-1994 14-09-1988 16-03-1989 01-03-1990 13-09-1988 16-03-1989 31-07-1993 10-11-1995 17-03-1989 25-10-1989 24-03-1989 13-11-1991 22-06-1989 22-04-1996 30-10-1989

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00341

HU	B	205010	30-03-1992
IE	B	61195	19-10-1994
IL	A0	87746	28-02-1989
IL	A1	87746	15-07-1992
IT	A0	8848349	14-09-1988
IT	A	1224886	24-10-1990
JP	A2	1151526	14-06-1989
KR	B1	131084	17-04-1988
LU	A	87335	06-04-1989
NL	A	8802275	03-04-1989
NO	A0	884052	13-09-1988
NO	A	884052	16-03-1989
NO	B	179434	01-07-1996
NO	C	179434	09-10-1996
NZ	A	226163	27-08-1991
PT	A	88492	01-10-1988
PT	B	88492	31-03-1993
SE	A0	8803221	13-09-1988
SE	A	8803221	16-03-1989
SE	C2	503279	13-05-1996
DE	A1	3830494	23-03-1989
GB	A0	8821443	12-10-1988
ZA	A	8806885	30-05-1990
GB	A0	8901898	15-03-1989
<hr/>			
JP	A	81057362	keine - none - rien
<hr/>			